Hanyoyin cututtuka na zuciya-jijiyoyin sun bambanta tsakanin Celebrex, Vioxx, da kuma tsofaffi NSAIDs.
Wannan labarin shine ɓangare na Arthritis Archives.
Edita Edita: A ranar 09/30/2004, Merck mai aikata laifuka na Vioxx, ya ba da rahotanni a duniya, ya dakatar da tallace-tallace na miyagun ƙwayoyi. A ranar 04/07/2005, bayan binciken da aka yi na maganin cututtukan maganin arthritis da ake kira NSAIDs da COX-2 masu hanawa, FDA ta sanar da shirin tsara tsarin.
Dattijan: Mayu 29, 2004
Binciken Kanada Kanada Celebrex Zasu Yi Amfani da Abincin Cutar Flammatory Don Tsofaffi
Mutanen da ke da alamun cututtuka na maganin wariyar launin fata sukan saba da wasu kwayoyi masu ba da zafin jiki, wadanda ba su da magungunan jini (NSAIDs) ko ɗaya daga cikin sabuwar ƙungiyar NSAIDS da ake kira cyclo-oxygenase-2 inhibitors ( COX-2 masu hanawa masu zabe ).
Ƙungiyoyin waɗanda ba zaɓaɓɓen NSAIDs an haɗa su tare da haɗarin haɗari na ƙetare zuciya ba. Kusan an san ko an kammala shi game da sakamakon zuciya na zuciya na COX-2 masu zaɓaɓɓe.
Lancet (2004; 363: 1751-56) ya bayyana sakamakon binciken Kanada wanda ya shafi mutane fiye da 130,000. Muhammad Mamdani daga Cibiyoyin Nazarin Harkokin Kasuwanci, Toronto, Kanada, da kuma abokan aiki sunyi nazari game da hadarin da ake samu na asibiti don cikewar zuciya saboda kusan:
- 14,500 mutane masu amfani da Vioxx mai hana COX-2 (rofecoxib)
- 19,000 mutane masu amfani da COX-2 inhibitor Celebrex (celecoxib)
- 5,400 mutane ta amfani da wadanda basu da zabi NSAIDs
- 100,000 mutane ba su yin amfani da wani NSAID aiki a matsayin ƙungiyar kulawa
Sakamakon binciken
Idan aka kwatanta da ƙungiyar kula da masu amfani da NSAID ba, sakamakon ya kasance:
- Mutane da ke amfani da Vioxx sun sami kashi 80% na hadarin samun shiga asibiti don rashin ciwowar zuciya.
- Mutane da ke amfani da NSAID ba wadanda ba zaɓaɓɓe sun sami haɗari na kashi 40 cikin dari na shiga don ƙuntatawar zuciya ba.
- Mutane da ke amfani da Celebrex suna da irin wannan shigarwar asibiti don rashin nasara na zuciya kamar yadda mutanen da basu taɓa yin amfani da NSAIDs ba.
Bambance-bambance tsakanin wadanda ba zaɓaɓɓe NSAIDS da masu kwantar da hankali na COX-2 ba don shiga cikin rashin ƙarfi na zuciya mai tsanani zai nuna cewa akwai bukatar buƙatar ƙira mai yawa, bazuwar, gwajin gwaji don sauƙaƙe nazarin.
Abubuwan da suka dace
- Celebrex (Celecoxib)
- Vioxx (Rofecoxib)
- COX-2 Masu hana Yan Zaɓuɓɓuka
- Ƙarin Game da NSAIDs
- Magungunan Arthritis
Source: COX-2 Mai hanawa zai iya zama Safest anti-inflammatory Drug ga tsofaffi, The Lancet Issue 29 May 2004
Da farko aka buga: 05/29/2004